search
Back to results

Accelerated Neuromodulation to Alleviate Cognitive Deficits Due to Cancer Therapy

Primary Purpose

Cancer

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)
Sponsored by
Kanchna Ramchandran
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cancer focused on measuring neuromodulation, chemo-brain

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Women or men with a history of non-metastatic cancer who have completed definitive curative cancer therapy
  • Received cytotoxic chemotherapy as a part of their therapy for cancer and at least one month has passed since the final cytotoxic chemotherapy treatment
  • ≥ 18 years of age at time of cancer diagnosis and receipt of chemotherapy
  • Patients must report subjective symptoms of "chemo-brain" (memory loss, difficulty with concentration, word-finding difficulties) with a FACT-Cog perceived cognitive impairment score < 60
  • Ability to sign informed consent and comply with study procedures

Exclusion Criteria:

  • Patients with a recurrence of cancer or those with current metastatic disease
  • Patients with a history or current diagnosis of brain metastasis
  • Patients with a history or current diagnosis of a primary brain tumor
  • Patients with a history of brain surgery or brain radiation
  • Patients receiving maintenance systemic therapy for cancer, other than endocrine therapy
  • Patients who cannot produce or request adequate medical record documentation to ensure they meet inclusion and exclusion criteria
  • Women who are currently pregnant
  • History of childhood cancer or receipt of chemotherapy in childhood (<age 18). Developmental insult to the PFC, can be associated with long-term, durable and sometime debilitating cognitive deficits. Hence, we avoid any cognitive confounds that maybe related to this issue.
  • Patients with a weight over 250 lbs., as these patients would not fit in the MRI scanner used in the protocol
  • Patients who require benzodiazepines for MRI due to claustrophobic anxiety
  • Patients with chest wall tissue expanders or other retained 7 Tesla MRI-incompatible metal. Any other specific contraindication to TMS or MRI not already listed above, including:
  • (a) any implanted device in the head, neck or upper body (e.g. cochlear implant, cranial or other electrodes, pacemaker or defibrillator, medication pump, stent, aneurysm clip, etc.)
  • (b) personal history of seizures or epilepsy, personal history of multiple concussions or unexplained loss of consciousness. This will be determined by physician judgement
  • History of adverse reaction to previous TMS or MRI exposure
  • Active substance use disorder in the past 6 months, excluding tobacco use disorder, as diagnosed by study physicians

Sites / Locations

  • University of Iowa Hospitals & Clinics

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or sham

Arm Description

Patients will participate in the prospective longitudinal research protocol over a period of 1.5 months. Treatment will include 8 visits of either accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or iTBS sham stimulation. Patients will be informed that iTBS sham stimulations will be part of the protocol (but will be blind to when treatment/sham will be administered).

Outcomes

Primary Outcome Measures

Mean changes in executive cognitive function between pre and post application of iTBS treatment protocol
Executive cognitive function will be quantified using technician administered Color Word Interference Test, Category Fluency, Tower of Hanoi, Card Sort and Strategy Application Task (Shallice &Burgess) tests, and the self-report Functional Assessment of Cancer Therapy - Cognitive Scale (FACT-COG) (Dyk et al.). Executive Function (EF) is measured by utilizing standardized test scores adapted from the Delis-Kaplan Executive Function Scales (D-KEFS battery) (Homack et al.). FACT-COG, Category Fluency and Strategy Application Task use raw scores. All EF measures used in this battery form a part of a normative database created and maintained by the principle investigator of this study. An overall score of EF is computed by averaging the Z scores of each test. Higher score on each test represents better performance.
Mean changes in brain metabolite concentrations between pre and post application of iTBS treatment protocol
Proton Magnetic Resonance Spectroscopy will be used to quantify brain metabolite concentrations in parts per million. Brain metabolites under evaluation include: glutamine, glutamate, N-acetyl aspartate, choline, and creatine.

Secondary Outcome Measures

Full Information

First Posted
June 10, 2021
Last Updated
September 15, 2023
Sponsor
Kanchna Ramchandran
Collaborators
American Cancer Society-Holden Comprehensive Cancer Society, Fraternal Order of Eagles (Iowa)
search

1. Study Identification

Unique Protocol Identification Number
NCT04966520
Brief Title
Accelerated Neuromodulation to Alleviate Cognitive Deficits Due to Cancer Therapy
Official Title
Repetitive Intermittent Accelerated Theta-burst Transcranial Stimulation(iTBS) as a Potential Intervention for Chemotherapy Induced Cognitive Deficits (CICD)- a Pilot Clinical Trial to Explore Feasibility and Efficacy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
June 1, 2021 (Actual)
Primary Completion Date
July 18, 2023 (Actual)
Study Completion Date
December 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Kanchna Ramchandran
Collaborators
American Cancer Society-Holden Comprehensive Cancer Society, Fraternal Order of Eagles (Iowa)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This project is aimed at the discovery of neuro-modulation techniques that may alleviate chemotherapy induced cognitive deficits (CICD), especially in executive (higher-order) cognitive function (EF).
Detailed Description
The specific aim for this study is to use magnetic resonance spectroscopy (MRS), self-report, and neuropsychological testing to identify changes in brain metabolite concentrations/ratios and changes in EF deficits associated with chemotherapy, before and after accelerated theta-burst transcranial stimulation (iTBS). The secondary aim is to assess for any association of changes in executive function with brain metabolite concentrations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer
Keywords
neuromodulation, chemo-brain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or sham
Arm Type
Experimental
Arm Description
Patients will participate in the prospective longitudinal research protocol over a period of 1.5 months. Treatment will include 8 visits of either accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS) or iTBS sham stimulation. Patients will be informed that iTBS sham stimulations will be part of the protocol (but will be blind to when treatment/sham will be administered).
Intervention Type
Other
Intervention Name(s)
Accelerated repetitive intermittent theta-burst transcranial stimulation (iTBS)
Intervention Description
Accelerated iTBS will be used to stimulate the regions of interest of mPFC and L-DLPFC nodes in cancer survivors or patients. Accelerated iTBS will be administered in a single half-day period to allow for a 50minutes interval between any two treatments to minimize interference effects between treatments. Thus, there will be ~10 minute sessions of stimulation x 2 applications per node x 2 nodes (L-DLPFC, mPFC) = 40 total minutes of daily stimulation - each session delivers 1800 pulses in a 5 Hz triplet burst frequency, 2 second trains with intertrain interval of 8 seconds; triplets occur with 50 Hz frequency, as per standard iTBS protocols for depression treatment. The treatment will be offered for five consecutive days.
Primary Outcome Measure Information:
Title
Mean changes in executive cognitive function between pre and post application of iTBS treatment protocol
Description
Executive cognitive function will be quantified using technician administered Color Word Interference Test, Category Fluency, Tower of Hanoi, Card Sort and Strategy Application Task (Shallice &Burgess) tests, and the self-report Functional Assessment of Cancer Therapy - Cognitive Scale (FACT-COG) (Dyk et al.). Executive Function (EF) is measured by utilizing standardized test scores adapted from the Delis-Kaplan Executive Function Scales (D-KEFS battery) (Homack et al.). FACT-COG, Category Fluency and Strategy Application Task use raw scores. All EF measures used in this battery form a part of a normative database created and maintained by the principle investigator of this study. An overall score of EF is computed by averaging the Z scores of each test. Higher score on each test represents better performance.
Time Frame
1.5 months
Title
Mean changes in brain metabolite concentrations between pre and post application of iTBS treatment protocol
Description
Proton Magnetic Resonance Spectroscopy will be used to quantify brain metabolite concentrations in parts per million. Brain metabolites under evaluation include: glutamine, glutamate, N-acetyl aspartate, choline, and creatine.
Time Frame
1.5 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women or men with a history of non-metastatic cancer who have completed definitive curative cancer therapy Received cytotoxic chemotherapy as a part of their therapy for cancer and at least one month has passed since the final cytotoxic chemotherapy treatment ≥ 18 years of age at time of cancer diagnosis and receipt of chemotherapy Patients must report subjective symptoms of "chemo-brain" (memory loss, difficulty with concentration, word-finding difficulties) with a FACT-Cog perceived cognitive impairment score < 60 Ability to sign informed consent and comply with study procedures Exclusion Criteria: Patients with a recurrence of cancer or those with current metastatic disease Patients with a history or current diagnosis of brain metastasis Patients with a history or current diagnosis of a primary brain tumor Patients with a history of brain surgery or brain radiation Patients receiving maintenance systemic therapy for cancer, other than endocrine therapy Patients who cannot produce or request adequate medical record documentation to ensure they meet inclusion and exclusion criteria Women who are currently pregnant History of childhood cancer or receipt of chemotherapy in childhood (<age 18). Developmental insult to the PFC, can be associated with long-term, durable and sometime debilitating cognitive deficits. Hence, we avoid any cognitive confounds that maybe related to this issue. Patients with a weight over 250 lbs., as these patients would not fit in the MRI scanner used in the protocol Patients who require benzodiazepines for MRI due to claustrophobic anxiety Patients with chest wall tissue expanders or other retained 7 Tesla MRI-incompatible metal. Any other specific contraindication to TMS or MRI not already listed above, including: (a) any implanted device in the head, neck or upper body (e.g. cochlear implant, cranial or other electrodes, pacemaker or defibrillator, medication pump, stent, aneurysm clip, etc.) (b) personal history of seizures or epilepsy, personal history of multiple concussions or unexplained loss of consciousness. This will be determined by physician judgement History of adverse reaction to previous TMS or MRI exposure Active substance use disorder in the past 6 months, excluding tobacco use disorder, as diagnosed by study physicians
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kanchna Ramchandran, MS, PHD
Organizational Affiliation
University of Iowa Hospitals & Clinics
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa Hospitals & Clinics
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Accelerated Neuromodulation to Alleviate Cognitive Deficits Due to Cancer Therapy

We'll reach out to this number within 24 hrs